Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed) | RFA HL 23 012

Opportunity Information: Apply for RFA HL 23 012

Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed) is a National Institutes of Health (NIH) funding opportunity (RFA-HL-23-012) designed to help research teams bridge the gap between basic discovery and a viable therapeutic development program. The central purpose is to provide early translational support to identify and define a credible lead compound or lead series (for either small molecules or biologics) that could eventually become a therapeutic agent for conditions within the National Heart, Lung, and Blood Institute (NHLBI) mission areas, including heart, lung, blood, and sleep diseases and disorders. In practical terms, the FOA is aimed at taking promising early findings and pushing them far enough along that they become development-ready, either by meeting the entry requirements for the NHLBI Catalyze Preclinical program or by becoming attractive to other development partners in the federal or private sector who can carry the work forward into preclinical optimization and, later, clinical development.

This opportunity uses the R33 grant mechanism and explicitly does not allow clinical trials, signaling that the work should remain in the non-clinical translational space. The emphasis is on product definition and preliminary lead identification rather than human testing. Applicants are expected to focus on the key steps needed to converge on a lead series: establishing a compelling rationale for the therapeutic approach, demonstrating tractable and reproducible activity, and generating the kinds of data that reduce early technical risk. While the notice text provided does not list specific experimental requirements, the overall framing makes clear that NHLBI is looking for projects that can move beyond exploratory biology and toward a more development-minded package, such as evidence that a candidate modality can be advanced, iterated, and positioned for formal preclinical optimization.

As part of the NHLBI Catalyze suite of innovation grants, this FOA functions as an earlier rung in a staged translational pipeline. The intent is not only to fund science, but to help teams reach a decision point where the project can either (1) transition into more advanced NHLBI-supported preclinical efforts or (2) be sufficiently de-risked to secure independent support from outside partners. This makes it particularly relevant for teams that have a strong starting concept but still need resources and structure to define a true therapeutic lead, clarify the proposed product profile, and generate the early development evidence that sophisticated funders and translational programs typically expect.

The opportunity is listed as discretionary and uses a grant funding instrument. It is associated with CFDA numbers 93.233 and 93.837 through 93.840. The award ceiling is $350,000, based on the source data provided. The original closing date is December 20, 2024, and the FOA record creation date is January 24, 2022. The expected number of awards is not specified in the provided excerpt.

Eligibility is broad and includes many common applicant categories across government, academia, nonprofit, and industry. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; small businesses; and other applicant types. The FOA also calls out additional eligible applicant groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible agencies of the federal government, Indian/Native American tribal governments other than federally recognized, and U.S. territories or possessions.

On the foreign eligibility side, the FOA draws a clear line: non-domestic (non-U.S.) entities (foreign organizations and foreign institutions) are not eligible to apply as applicant organizations. At the same time, it allows non-domestic components of U.S. organizations to participate, and it allows foreign components as defined in the NIH Grants Policy Statement. That structure is common in NIH funding where the prime applicant must be U.S.-based, but parts of the work may be performed through allowable foreign collaborations when well-justified.

Overall, this FOA is best understood as an early translational push for therapeutic concepts that are still in the stage of selecting and justifying a lead or lead series, rather than optimizing a mature candidate or running human studies. It is meant for projects that can articulate a clear path to a defined therapeutic product concept in NHLBI-relevant diseases, generate development-relevant evidence around that concept, and then hand off into a preclinical optimization pathway, either through NHLBI Catalyze programs or external partners.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233, 93.837, 93.838, 93.839, 93.840.
• This funding opportunity was created on 2022-01-24.
• Applicants must submit their applications by 2024-12-20. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $350,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA HL 23 012

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: